跳至主要内容
临床试验/ACTRN12606000410550
ACTRN12606000410550招募中1 期

A Phase 1, Randomized, Double-Blinded, Placebo-Controlled, Single Center Trial to Assess the Safety, Tolerability, and Pharmacokinetics of AV411 in Healthy Subjects

Avigen, Inc.0 个研究点目标入组 16 人开始时间: 2006年9月19日最近更新:
适应症

试验速览

阶段
1 期
状态
招募中
发起方
Avigen, Inc.
入组人数
16

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 70 Years(—)
性别
All

入选标准

  • Nonsmoking.-No clinical abnormality in laboratory and urine analyses.-Normal renal function Glomerular Filtration Rate (GFR) >90 mL/min.-Liver enzymes less than twice the upper limit of normal.-Electrocardiogram within normal limits at screening.-Willing to use barrier contraceptive during the period of the study.-Negative pregnancy test on Study Day 1 for female subjects of child-bearing potential.

排除标准

  • Known hypersensitivity to Pinatos or its components.-Conditions which might affect drug absorption, metabolism or excretion.-Untreated mental illness, current drug addiction or abuse or alcoholism.-Donated blood in the past 90 days or have poor peripheral venous access.-Platelets <100,000 per mm3 or a history of thrombocytopenia.-Confirmed diagnosis of chronic liver disease.-Positive for HIV.-Female subjects who are pregnant or nursing mothers.

研究者

发起方
Avigen, Inc.

相似试验